LNAI
Lunai Bioworks Inc.

3,308
Mkt Cap
$17.21M
Volume
523,136.00
52W High
$14.00
52W Low
$0.63
PE Ratio
-0.09
LNAI Fundamentals
Price
$0.7344
Prev Close
$0.8179
Open
$0.746
50D MA
$0.9472
Beta
1.32
Avg. Volume
173,667.65
EPS (Annual)
-$10.78
P/B
-1.31
Rev/Employee
$0.00
$57.65
Loading...
Loading...
News
all
press releases
Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC
Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC PR Newswire...
PR Newswire·2d ago
News Placeholder
More News
News Placeholder
Lunai Bioworks, Inc. Issues Letter to Shareholders
Lunai Bioworks, Inc. Issues Letter to Shareholders Lunai Bioworks, Inc. Issues Letter to Shareholders PR Newswire SACRAMENTO, Calif., Feb. 9, 2026 SACRAMENTO, Calif., Feb. 9, 2026 /PRNewswire...
PR Newswire·6d ago
News Placeholder
Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data
Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data Lunai Bioworks (NASDAQ: LNAI...
PR Newswire·6d ago
News Placeholder
Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons
Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard...
PR Newswire·19d ago
News Placeholder
Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery
Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use...
PR Newswire·20d ago
News Placeholder
Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market
Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market Lunai Bioworks Identifies Three...
PR Newswire·2mo ago
News Placeholder
LNAI Stock Soars Pre-Market After Immune Cell Therapy Gains Licensee Interest
The cell therapy, Dendritic Cell Combination Therapy (DCCT), achieved complete regression of both primary and metastatic pancreatic tumors with no recurrence in humanized preclinical models.
Stocktwits·3mo ago
News Placeholder
Top Biotech Stocks To Follow Now - November 5th
Danaher, Vertex Pharmaceuticals, Recursion Pharmaceuticals, Moderna, and Lunai Bioworks are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are...
MarketBeat·3mo ago
<
...
1
>

Latest LNAI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.